79250-48-9

Upstream product

• 2150-46-1 Methyl 2,5-dihydroxybenzoate 
• 106-95-6 allyl bromide 
• 79250-47-8 5-allyloxy-2-hydroxy-benzoic acid methyl ester 
• 490-79-9 2,5-dihydroxybenzoic acid. 

Downstream Products

• 959861-59-7 methyl 2-((R)-2,3-dihydroxypropoxy)-5-((S)-2,3-dihydroxypropoxy)benzoate 
• 91910-49-5 2,5-bis(allyloxy)benzoic acid 
• 959861-51-9 methyl 5-((R)-2,3-bis(sulfooxy)propoxy)-2-((S)-2,3-bis(sulfooxy)propoxy)benzoate 
• 959861-61-1 5-((R)-2,3-dihydroxypropoxy)-2-((S)-2,3-dihydroxypropoxy)benzoic acid 
• 959861-52-0 2-((R)-2,3-bis(sulfooxy)propoxy)-5-((S)-2,3-bis(sulfooxy)propoxy)benzoic acid 

Relevant academic research and scientific papers

A Structure-Reactivity Relationship of the Tandem Asymmetric Dihydroxylation on a Biologically Relevant Diene: Influence of Remote Stereocenters on Diastereofacial Selectivity

The Sharpless asymmetric dihydroxylation (AD) finds widespread use in natural product and drug molecule syntheses, in part, due to its efficiency and predictability. However, the tandem AD of dienes is much less studied, but important in complex molecular synthesis. Herein, a biologically relevant tandem AD is reported, and several anomalies are discovered with the accepted model. These include the formation of unpredicted diastereoisomers, with matched and mismatched stereocenters contradicting the Sharpless mnemonic device. From a structural analysis of the tandem AD, we present a strategy to improve asymmetric induction in sterically hindered alkenes using double diastereodifferentiation from a 9-bond distant stereocenter. A theoretical justification for the unpredicted stereoselectivity, accounting for the influence of steric hindrance and pre-installed chirality, is proposed.

GLYCOMIMETICS FOR USE FOR THE TREATMENT OF VASCULAR CALCIFICATION AND/OR ENDOTHELIAL DYSFUNCTION

The present invention relates to the use of glycomimetic compounds for the treatment of vascular calcification and/or endothelial dysfunction, particularly the use of small molecule mimetics of heparin/heparan sulfate, such as compounds according to formula (A), (B), (C) or (D), or pharmaceutically acceptable derivatives thereof

Novel heparin/heparan sulfate mimics as inhibitors of HGF/SF-induced MET activation

The synthesis of simple, non-sugar glycosaminoglycan (GAG) mimics has been achieved and the analogues evaluated for their ability to inhibit the activation of the MET receptor by hepatocyte growth factor/scatter factor (HGF/SF).